Výsledky vyhledávání - "Yoshikatsu Majikawa"

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin

Autor: Yasir J. Sepah, Quan Dong Nguyen, Yusuke Yamaguchi, Tetsuro Otsuka, Yoshikatsu Majikawa, Michael Reusch, Tadao Akizawa

Publikováno v: Kidney International Reports. 7:763-775

Roxadustat is an orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that represents a novel therapeutic option for patients with anemia of chronic kidney disease (CKD).Conducted in Japan, CL-0307 (NCT02952092) and CL-310

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c3866faa9be592f927f528d9186281
https://doi.org/10.1016/j.ekir.2022.01.1045

Zobrazit plný text záznamu

Roxadustat (Evrenzo® tablet), a therapeutic drug for renal anemia: pharmacological characteristics and clinical evidence in Japan

Autor: Asami Murata, Mizue Ashizaki, Tohru Ugawa, Yoshikatsu Majikawa

Publikováno v: Folia Pharmacologica Japonica. 156:187-197

Roxadustat (Evrenzo® tablet) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Roxadustat has been approved for the treatment of renal anemia in patients on dialysis in September 2019 in Japan. By inhibiting HIF-PH, roxadust

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5bcf880882a8628ceed8ab7c0c3b485
https://doi.org/10.1254/fpj.21001

Zobrazit plný text záznamu

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan

Autor: Michael Reusch, Yusuke Yamaguchi, Manabu Iwasaki, Tadao Akizawa, Yoshikatsu Majikawa

Publikováno v: J Am Soc Nephrol

Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. Methods This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to darbe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c27810510e223d17067123b3ce20b65
https://doi.org/10.1681/asn.2019060623

Zobrazit plný text záznamu

Authors’ Reply

Autor: Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch

Publikováno v: Journal of the American Society of Nephrology. 32:1005-1007

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ff0e1e62d6de190f73a131f49d21a92
https://doi.org/10.1681/asn.2021010051

Zobrazit plný text záznamu

Authors’ Reply

Autor: Tadao, Akizawa, Manabu, Iwasaki, Yusuke, Yamaguchi, Yoshikatsu, Majikawa, Michael, Reusch

Publikováno v: J Am Soc Nephrol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd60f4e52b72cf7ce5d283d7cec9f1dc
https://doi.org/10.1681/asn.2020071096

Zobrazit plný text záznamu

[Roxadustat (Evrenzo

Autor: Tohru, Ugawa, Mizue, Ashizaki, Asami, Murata, Yoshikatsu, Majikawa

Publikováno v: Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 156(3)

Roxadustat (Evrenzo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::090d8aa7fd317189c4a6213c7b90ec6d
https://pubmed.ncbi.nlm.nih.gov/33952849

Zobrazit plný text záznamu

MO002OPHTHALMOLOGICAL EFFECTS OF ROXADUSTAT IN THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS ON DIALYSIS IN A PHASE 3, RANDOMISED, DOUBLE-BLIND, ACTIVE-COMPARATOR CONVERSION STUDY

Autor: Tadao Akizawa, Michael Reusch, Yasir J. Sepah, Yoshikatsu Majikawa, Quan Dong Nguyen, Yusuke Yamaguchi

Publikováno v: Nephrology Dialysis Transplantation. 35

Background and Aims Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in China for the treatment of dialysis-dependent (DD) and non–dialysis-dependent chronic kidney disease (CKD) anaemia,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9e3ec600e695c2334fbac8a999396eb
https://doi.org/10.1093/ndt/gfaa140.mo002

Zobrazit plný text záznamu

ς Receptor Ligand-Induced Up-Regulation of the H+/Peptide Transporter PEPT1 in the Human Intestinal Cell Line Caco-2

Autor: Akira Yamamoto, Vadivel Ganapathy, Frederick H. Leibach, Naoki Okada, Sayoko Umehisa, Yoshikatsu Majikawa, Takuya Fujita

Publikováno v: Biochemical and Biophysical Research Communications. 261:242-246

We determined the effects of (+)pentazocine, a selective sigma(1) ligand, on the uptake of glycylsarcosine (Gly-Sar) in the human intestinal cell line Caco-2 which expresses the low affinity/high capacity peptide transporter PEPT1. Confluent Caco-2 c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971c8acab02fbbb6cd462cea77af53ff
https://doi.org/10.1006/bbrc.1999.1026

Zobrazit plný text záznamu

Methodology for evaluating inflammation induction potential of enteral absorption enhancers: Epithelial permeability enhancement via histamine receptors

Autor: Hidenori Obata, Shozo Muranishi, Nao Imaoka, Yoshikatsu Majikawa, Tomomi Uchiyama, Kayoko Sasaki, Masahiro Murakami, Yutaka Tomoda, Hiroyuki Tatsumi

Publikováno v: Drug Delivery System. 13:107-113

Proinflammatory mediators such as histamine, platelet activating factor and nitric oxide increase intestinal epithelial permeability and lead to disrupt its barrier function. ChemicalIy induced increase in the epithelial permeability could be mediate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b873108bfac7e62875186ae552cc8075
https://doi.org/10.2745/dds.13.107

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání